ClinicalTrials.gg
RecruitingNCT07491900Updated Mar 25, 2026

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of HB2198 in Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) and Extra-renal Lupus (ERL), sponsored by Hinge Bio. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Hinge Bio · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Lupus Nephritis with a site in Australia — 5 open to participants now, 7 under way, none of them phase 3. Lupus Nephritis · Australia.

Planned enrollment
20th of 24
30 · median 110
Started
2026
the only one that year
Phase 1
4 of 24
3 open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Hinge Bio

Among the 24 studies in Lupus Nephritis with a site in Australia, this one is the 20th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1, and was the 24th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

5 of the 24 studies in Lupus Nephritis with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lupus Nephritis with a site in Australia, or all of them as a file.
02

Study summary

This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with moderately to severely active systemic lupus erythematosus (SLE), including lupus nephritis and extra renal lupus. Approximately 30 participants will receive two intravenous doses of HB2198 and be followed for 12 months to assess safety, B cell depletion, disease activity, immunologic biomarkers, and renal outcomes.

Read the detailed description

HB2198 is a novel tetravalent bispecific antibody engineered for enhanced B-cell depletion through dual CD19/CD20 targeting and optimized Fc mediated effector function. The study uses a modified 3+3 dose escalation design, enrolling sequential cohorts to receive HB2198 IV on Day 1 and Day 8. Safety, dose limiting toxicities, pharmacokinetics, pharmacodynamics, and immunogenicity will be assessed. Participants will undergo comprehensive disease activity assessments using SLEDAI 2K, PGA, LupusQoL, FACIT Fatigue, and renal response metrics. Total participation is about 13 months.

03

Conditions studied

  • Systemic Lupus Erthematosus (SLE)
  • Lupus Nephritis (LN)
  • Extra-renal Lupus (ERL)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Meet 2019 ACR / 2023 EULAR SLE classification criteria

      • Moderate or high disease activity (SLEDAI 2K ≥6; PGA ≥1)
      • LN participants: confirmed active Class III/IV ± V or Class V LN; proteinuria ≥0.8 g/g; ≥30 mL/min/1.73 m²
      • ERL participants: inadequate response/intolerance to ≥1 standard SLE therapy
      • Positive ANA (≥1:80) or SLE associated autoantibodies
      • Required minimum lab values (lymphocytes ≥500/µL, B cells ≥25/µL, ≥1000/mm³, IgG ≥600 mg/dL, etc.)
      • Women of : negative pregnancy test; required
      • Voluntary

Exclusion criteria

Exclusion Criteria:

  • (Key) Inclusion Criteria:

    • Meet 2019 ACR / 2023 EULAR SLE classification criteria
    • Moderate or high disease activity (SLEDAI 2K ≥6; PGA ≥1)
    • LN participants: confirmed active Class III/IV ± V or Class V LN; proteinuria ≥0.8 g/g; ≥30 mL/min/1.73 m²
    • ERL participants: inadequate response/intolerance to ≥1 standard SLE therapy
    • Positive ANA (≥1:80) or SLE associated autoantibodies
    • Required minimum lab values (lymphocytes ≥500/µL, B cells ≥25/µL, ≥1000/mm³, IgG ≥600 mg/dL, etc.)
    • Women of : negative pregnancy test; required
    • Voluntary

(Key) Exclusion Criteria:

  • Anti CD19 or anti CD20 therapy within 6 months
  • Active CNS lupus
  • Significant cardiovascular, pulmonary, hepatic, or uncontrolled systemic disease
  • Active infection or recent serious infection
  • Positive or ; infection
  • Major surgery within 4 weeks
  • Prior organ or stem cell transplant
  • Current pregnancy or breastfeeding
  • Recent IVIg or plasmapheresis (\<3 months)
  • within 30 days
  • Any condition judged unsuitable by Investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HB2198

    Drug: HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody with Dual Fc Domains administered via IV infusion on Day 1 and Day 8. There are 8 Planned dose levels: 0.1 mg/kg → 16 mg/kg

    Drug: HB2198

Interventions

  • DrugHB2198

    HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody with Dual Fc Domains

06

What researchers measure

Primary outcomes

  1. Number of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Safety and tolerability will be assessed primarily by the incidence of TEAEs and SAEs. Supporting safety data (e.g., clinical laboratory values, vital signs, ECG results, physical examinations, and renal function assessments) will be reviewed descriptively to aid interpretation of tolerability but will not be reported as separate outcome measures.

    Time frame: Day 1, Day 8, Day 14, Day 29

  2. Maximum tolerated dose (MTD)

    MTD will be determined based on the incidence of dose-limiting toxicities (DLTs) according to protocol-defined criteria. Laboratory results, vital signs, ECGs, physical examinations, and renal assessments will be used to evaluate DLTs but will not be individually reported as outcome measures.

    Time frame: Day 1, Day 8, Day 14, Day 29

  3. Number of participants experiencing dose-limiting toxicities (DLTs)

    DLTs will be evaluated based on protocol-defined criteria. Supporting safety data (e.g., labs, vitals, ECGs, physical exams, renal assessments) will be used to determine DLT classification but will not be reported as separate outcome measures.

    Time frame: Day 1, Day 8, Day 14, Day 29

  4. Recommended Phase 2 Dose (RP2D)

    The RP2D will be selected using an integrated assessment of DLTs, TEAEs, and overall tolerability, based on protocol-defined safety criteria. Clinical laboratory results, vital signs, ECGs, physical examinations, and renal assessments will be used to inform dose selection but will not be individually reported.

    Time frame: Day 1, Day 8, Day 14, Day 29

Secondary outcomes

  1. To characterize the pharmacokinetic (PK) profile of HB2198

    Concentration of HB2198 and PK parameters such as, area under the concentration versus time curve (AUC)

    Time frame: Multiple timepoints collected before and after infusion on dosing days (Day 1, Day 8), and during the follow-up period on Day 14, Day 29, Month 3, Month 12

  2. To characterize the pharmacokinetic (PK) profile of HB2198

    Concentration of HB2198 and PK parameters such as maximum drug concentration (Cmax)

    Time frame: Multiple timepoints collected before and after infusion on dosing days (Day 1, Day 8), and during the follow-up period on Day 14, Day 29, Month 3, Month 12

  3. To characterize the pharmacokinetic (PK) profile of HB2198

    Concentration of HB2198 and PK parameters such as time to maximum plasma concentration (tmax)

    Time frame: Multiple timepoints collected before and after infusion on dosing days (Day 1, Day 8), and during the follow-up period on Day 14, Day 29, Month 3, Month 12

  4. To evaluate the development of anti-drug antibodies (ADAs)

    Proportion of participants developing ADAs

    Time frame: Multiple timepoints collected before and after infusion on dosing days (Day 1, Day 8), and during the follow-up period on Day 14, Day 29, Month 3, Month 12

  5. To evaluate B-cell depletion and other pharmacodynamic changes

    B cell depletion dynamics (depth, duration, subsets)

    Time frame: Screening, Day 1, Day 8, Day 14, Day 29, Month 2, Month 3, Month 6, Month 9, Month 12/End of Study

  6. To evaluate change from baseline in systemic lupus disease activity

    • Change from baseline in SLEDAI 2K

    Time frame: Screening, Day 1, Day 14, Day 29, Month 2, Month 3, Month 4, Month 6, Month 9, Month 12/End of Study

  7. To evaluate change from baseline in systemic lupus disease activity

    • Achievement of Lupus Low Disease Activity State (LLDAS)

    Time frame: Screening, Day 1, Day 14, Day 29, Month 2, Month 3, Month 4, Month 6, Month 9, Month 12/End of Study

  8. To evaluate change from baseline in systemic lupus disease activity

    • Renal response: CRR/PRR

    Time frame: Day 29, Month 3, Month 6, Month 9, Month 12

  9. To evaluate change from baseline in systemic lupus disease activity

    • Change in LupusQoL

    Time frame: Screening, Day 1, Day 14, Day 29, Month 2, Month 3, Month 4, Month 6, Month 9, Month 12/End of Study

  10. To evaluate change from baseline in systemic lupus disease activity

    • Change in FACIT Fatigue scores

    Time frame: Screening, Day 1, Day 14, Day 29, Month 2, Month 3, Month 4, Month 6, Month 9, Month 12/End of Study

  11. To evaluate change from baseline in systemic lupus disease activity

    • Change in Physician Global Assessment (PGA)

    Time frame: Screening, Day 1, Day 14, Day 29, Month 2, Month 3, Month 4, Month 6, Month 9, Month 12/End of Study

07

Study locations

1 of 1 sites recruiting
  • Investigational site
    Brisbane, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — This is still being actively discussed. A decision will be made during the course of the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Oct 2027, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Mar 25, 2026
StartEst.
Mar 23, 2026
Primary completionEst.
Oct 24, 2027
CompletionEst.
Oct 24, 2028
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07491900
Lead sponsor
Hinge Bio
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Mar 23, 2026 (estimated)
Primary completion
Oct 24, 2027 (estimated)
Completion
Oct 24, 2028 (estimated)
Last update
Mar 25, 2026

Study contacts

Joshua Pelham
Contact
joshua.pelham@hingebio.com
1-415-378-4738
Kristen Quigley
Contact
kristen.quigley@hingebio.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion